TISOCALCITATE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C31H48O5
Molecular Weight	500.7098
Optical Activity	UNSPECIFIED
Defined Stereocenters	7 / 7
E/Z Centers	3
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)OC(=O)C(C)(C)[C@H](O)\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C3\C[C@@H](O)C[C@H](O)C3=C

InChI

InChIKey=AUMBXYDXKLLKEK-BGMQPCSBSA-N

InChI=1S/C31H48O5/c1-19(2)36-29(35)30(5,6)28(34)15-10-20(3)25-13-14-26-22(9-8-16-31(25,26)7)11-12-23-17-24(32)18-27(33)21(23)4/h10-12,15,19-20,24-28,32-34H,4,8-9,13-14,16-18H2,1-3,5-7H3/b15-10+,22-11+,23-12-/t20-,24-,25-,26+,27+,28-,31-/m1/s1

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15968262 | https://adisinsight.springer.com/drugs/800018814 | DOI: 10.1016/j.jaad.2003.11.041 | DOI: 10.1016/j.jaad.2003.11.042 | DOI: 10.1016/j.jaad.2003.10.541

Tisocalcitate is the vitamin D derivative. Tisocalcitate ointment is currently in phase 2 clinical development for mild to moderate psoriasis. Early studies have shown that, unlike other vitamin D3 analogues, tisocalcitate does not affect calcium metabolism. Tisocalcitate ointments were tolerated well and were safe to use on healthy skin. Tisocalcitate had been in phase II clinical trial for the treatment of psoriasis. However, this development was discontinued.

Approval Year

PubMed

Title	Date	PubMed
Therapeutic options in the treatment of psoriasis and atopic dermatitis.	2005-07	15968262

Sample Use Guides

In Vivo Use Guide

25 ug/g of Tisocalcitate ointment on 45% BSA, 50 ug/g of Tisocalcitate ointment on 45% BSA and twice daily 50 ug/g of Tisocalcitate ointment on 45% BSA.

Route of Administration: Topical

Name

Type

Language

ZK-156942

Preferred Name

English

TISOCALCITATE

Official Name

English

TISOCALCITATE [USAN]

Common Name

English

tisocalcitate [INN]

Common Name

English

ZK156942

Code

English

Classification Tree Code System Code

NCI_THESAURUS

C39713